Coverage
-
December 22, 2022
A Delaware federal judge rightly invalidated claims in a Roche unit's patents for a lung disease drug it paid $8 billion to acquire and properly held that a Novartis unit's generic version doesn't infringe, the Federal Circuit said Thursday.
3 other articles on this case.
View all »